Orforglipron
Also known as: LY-3502970
Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes
Overview
First oral non-peptide GLP-1 completing Phase 3 trials. Achieves substantial weight loss without injections, refrigeration, or dietary restrictions, with clinical evidence of 12.4% weight reduction at 72 weeks.
Key benefits
- Significant weight loss (up to 12.4% at 72 weeks)
- Robust diabetes control (HbA1c reduction 1.3-1.6%)
- Once-daily oral tablet format
- No refrigeration or food restrictions required
- Reduced cardiovascular risk markers
Mechanism of action
Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.1% oral bioavailability with 29-49 hour half-life.
Molecular data
- Type
- Small-molecule GLP-1R agonist
- Half-life
- 25-68 hours
Sequence
Not applicable - synthetic small molecule
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Obesity Without Diabetes
Most effectiveATTAIN-1 demonstrated 12.4% weight loss (27.3 lbs) at 72 weeks with 36mg dose; 59.6% achieving ≥10% weight loss.
Obesity With Type 2 Diabetes
Most effectiveATTAIN-2 showed 10.5% weight loss with 72.8% achieving ≥5% weight loss.
Cardiometabolic Risk Reduction
EffectiveImprovements in waist circumference, systolic blood pressure (8-12 mmHg), triglycerides (-20-30%).
Prediabetes Prevention
Most effective91% achieved near-normal blood sugar levels versus 42% with placebo.
Type 2 Diabetes
Type 2 Diabetes Management
Most effectiveACHIEVE-1 Phase 3 trial showed HbA1c reductions of 1.3-1.6% from 8.0% baseline; 76.2% achieving HbA1c <7%.
Insulin Resistance Improvement
EffectiveSignificant improvements in insulin sensitivity indices within 4 weeks of therapy initiation.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Oral
Once-daily oral tablet requiring no reconstitution. Can be taken with or without food or water at any time of day.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Type 2 diabetes initiation | 3mg daily | Once daily, any time | Oral tablet |
| Type 2 diabetes moderate control | 12mg daily | Once daily, any time | Oral tablet |
| Type 2 diabetes optimal control | 36mg daily | Once daily, any time | Oral tablet |
| Weight loss initiation | 6mg daily | Once daily, any time | Oral tablet |
| Weight loss optimization | 36mg daily | Once daily, any time | Oral tablet |
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Semaglutide
AvoidBoth are GLP-1 agonists; combining increases severe hypoglycemia and excessive GI adverse effects.
Tirzepatide
AvoidDual GIP/GLP-1 agonist overlaps with GLP-1 mechanism; combination contraindicated.
Liraglutide
AvoidAnother GLP-1 agonist; concurrent use contraindicated due to overlapping mechanisms.
Insulin
MonitorOrforglipron enhances insulin sensitivity; may require significant insulin dose reduction.
Metformin
SynergisticComplementary mechanisms for diabetes management; Phase 3 trials showed enhanced efficacy.
BPC-157
CompatibleNo known interactions; may support gut health and potentially mitigate GI adverse effects.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Week 1-2
Appetite reduction typically within 1-3 days; mild to moderate nausea common
- Week 2-4
Gradual weight loss begins (0.5-2 lbs per week); improved blood sugar control
- Week 4-12
Reduced food cravings; GI adverse effects generally diminish; metabolic markers improving
- Week 12-36
Continued progressive weight loss without plateau
- Week 36+
Long-term therapy well-tolerated; sustained benefits at 72 weeks
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Diarrhea (more prevalent than with injectable GLP-1s)
- Nausea (typically improves after first month)
- Appetite reduction
Stop signs — stop and seek advice
- Severe or persistent abdominal pain radiating to back (potential pancreatitis)
- Neck lumps, hoarseness, difficulty swallowing, or neck swelling
- Severe nausea/vomiting preventing adequate nutrition or hydration
- Signs of severe hypoglycemia (confusion, sweating, rapid heartbeat)
- Suicidal thoughts, severe depression, or significant mood changes
- Vision changes or persistent eye pain
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy and breastfeeding
Monitoring
- Monitor for signs of acute pancreatitis
- Adjust other diabetes medications to prevent hypoglycemia
- Monitor for gallbladder disease symptoms with rapid weight loss
- Watch for suicidal thoughts or significant mood changes
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- Intact tablet packaging with proper labeling, batch numbers, and expiration dates
- Uniform tablet appearance without discoloration, chipping, or cracking
- Proper storage at room temperature (15-30°C)
Warning signs
- As of late 2025, orforglipron remains investigational only; any product claiming FDA approval is fraudulent
Stop signs — don't use
- Discolored, crumbling, or damaged tablets indicate improper storage
- Moisture exposure or humidity damage
References
Primary literature and clinical-trial data informing this entry.
ATTAIN-1 Phase 3 Trial (Obesity)
2025
3,127 adults; 72 weeks. 36mg dose achieved 12.4% weight loss (27.3 lbs) versus 2.1% placebo. First oral small-molecule GLP-1 completing Phase 3.
ATTAIN-2 Phase 3 Trial (Obesity + Type 2 Diabetes)
2025
1,613 adults; 72 weeks. 36mg dose achieved 10.5% weight loss with 72.8% achieving ≥5% weight loss.
ACHIEVE-1 Phase 3 Trial (Type 2 Diabetes)
2025
559 adults; 40 weeks. All doses significantly reduced HbA1c by 1.3-1.6%; 76.2% achieved HbA1c <7%.
Phase 2 Obesity Study
2023
272 adults; 36 weeks. Achieved up to 14.7% mean weight reduction at 36 weeks with 45mg dose.
Last updated . How this page was sourced is described in the methodology.